This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is SPDR S&P Health Care Equipment ETF (XHE) a Hot ETF Right Now?
by Sweta Killa
Smart Beta ETF report for XHE
DexCom (DXCM) Meets Q1 Earnings Estimates, Raises '18 View
by Zacks Equity Research
Solid contribution from Sensor revenues, Transmitter revenues and Receiver revenues drive DexCom's (DXCM) Q1 results.
Is SPDR S&P Health Care Equipment ETF (XHE) a Hot ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XHE
DexCom (DXCM) Gets FDA Approval for G6 CGM Monitoring System
by Zacks Equity Research
DexCom (DXCM) is a leading player in the global CGM markets.
DexCom (DXCM) Surpasses Earnings & Revenue Estimates in Q4
by Zacks Equity Research
DexCom (DXCM) rides high on strength in all segments in Q4.
Will Admissions Drive Universal Health's (UHS) Q4 Earnings?
by Zacks Equity Research
Solid performances at Acute Care and Behavioral Health segments are likely to boost Universal Health's (UHS) Q4 results.
Patterson Companies (PDCO) Q3 Earnings: What's in Store?
by Zacks Equity Research
Diverse product portfolio and strong veterinary business prospects to drive Patterson Companies (PDCO) in Q3. However, sluggishness in the Dental-Supply segment is a woe.
Will Admissions Drive Universal Health's (UHS) Q4 Earnings?
by Zacks Equity Research
Solid performances at Acute Care and Behavioral Health segments are likely to boost Universal Health's (UHS) Q4 results.
Why DexCom (DXCM) Might Surprise This Earnings Season
by Zacks Equity Research
DexCom (DXCM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
DexCom Estimates Strong Revenue Figures for Q4 and 2017
by Zacks Equity Research
Dexcom (DXCM) to gain from strong sensor volumes, international revenues and expanding worldwide patient base in 2018.
The Zacks Analyst Blog Highlights: Bio-Rad Laboratories, Mazor Robotics, Tactile Systems, Eli Lilly and DexCom
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bio-Rad Laboratories, Mazor Robotics, Tactile Systems, Eli Lilly and DexCom
4 MedTech Stocks to Explode in 2018
by Zacks Equity Research
Standing at the threshold of 2018 it is imperative for the investors to find the means which can dilute the macroeconomic woes and help them gain more.
DexCom (DXCM) Banks on Collaborations, Competition Rife
by Zacks Equity Research
DexCom's (DXCM) collaborative agreements should bring in cash in the form of milestone payments and royalties, and help expand product portfolio.
Lilly Inks Deal to Include Dexcom Products in Diabetes System
by Zacks Equity Research
Lilly (LLY) enters into a development agreement with DexCom to integrate the latter's continuous glucose monitoring into its Connected Diabetes Ecosystem.
DexCom-Lily Partnership to Boost CGM Platform, Customer Base
by Zacks Equity Research
DexCom (DXCM) continues to sign deals to boost CGM platform adoption.
DexCom (DXCM) Q3 Loss Narrower Than Expected, Revenues Meet
by Zacks Equity Research
DexCom (DXCM) rides high on Sensor and Transmitter revenues in Q3.
Why Is DexCom (DXCM) Up 11.6% Since the Last Earnings Report?
by Zacks Equity Research
DXCM reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
DexCom (DXCM) in Focus: Stock Moves 6.7% Higher
by Zacks Equity Research
DexCom, Inc. (DXCM) was a big mover last session, as the company saw its shares rise nearly 7% on the day after the company reported better-than-expected third quarter, 2017 results.
DexCom (DXCM) Q2 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
DexCom (DXCM) recorded narrower-than-expected loss in the second quarter owing to robust growth in international space, particularly Germany.
Company News for June 06, 2017
by Zacks Equity Research
Companies in the News are: HLF,P,VZ,PBYI,DXCM,AAPL
Strength Seen in DexCom (DXCM): Stock Adds 5% in Session
by Zacks Equity Research
DexCom, Inc. (DXCM) shares rose over 5% in the last trading session.
DexCom (DXCM) Stock Rallies on Apple Watch Partnership
by Ryan McQueeney
Shares of DexCom (DXCM) popped nearly 5% in afternoon trading Monday after Apple (AAPL) announced that it has partnered with the company to deliver glucose monitoring on its latest Apple Watch operating system.
DexCom (DXCM) Down 9.6% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
DexCom (DXCM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
DexCom (DXCM) Q1 Loss Narrower than Expected, Revenues Miss
by Zacks Equity Research
DexCom Inc. (DXCM) reported a loss of 49 cents per share in the first quarter of 2017, narrower than the Zacks Consensus Estimate of a loss of 55 cents.
Medical Product Q1 Earnings Due on May 2: BDX, DXCM & More
by Zacks Equity Research
The medical product sector shines bright at the moment owing to the prevalence of minimally invasive surgeries, liquid biopsy tests, and use of IT for ensuring quick and improved patient care among other things.